People on various combination trials are tested for MRD after a few months of treatment. I wonder if anyone of you has been tested with NGS (Next Generation Sequencing). NGS is supposed to be a lot more precise when assessing MRD negative status.
I know it has a cost that might not be covered by the trial or insurance. Nonetheless we only need a few CLL cells left to relapse and I think it would make sense to use NGS to have a deeper analysis in the blood and bone marrow.
I am very interested to know about anyone's experience with NGS, if any and also to find out how much better NGS is compared to flow cytometry or what other technology is used today to assess MRD status.
Reply Like (1)
More